Anaveon emerged out of University of Zurich in late 2017 with the support of Novartis-backed UZH Life Sciences Fund and the corporate has now also invested directly.

There is a great interest among tech transfer leaders in connecting to corporate venture capital funds to benefit their spinouts – corporations do not simply provide capital but also offer industry expertise and potentially access to a vast clientbase. But convincing corporate venturers to invest in spinouts at launch can be tricky because technologies are…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.